secwatch.observer — SEC 8-K summary
======================================

Issuer:     XOMA Royalty Corp (XOMA)
CIK:        0000791908
Form:       8-K
Filed at:   2024-05-09T23:59:59+00:00
Accession:  0001193125-24-134777
Event type: earnings
Sentiment:  positive
Materiality: 0.85
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

XOMA Q1 net loss $8.6M; FDA approves OJEMDA triggering $9M milestone
--------------------------------------------------------------------

- Q1 revenue $1.5M (vs $0.4M YoY) on $1M AVEO milestone; net loss $8.6M (vs $9.8M YoY).
- FDA approved Day One's OJEMDA; XOMA earned $9M milestone and will receive mid-single digit royalties.
- Acquired Kinnate Pharmaceuticals for $2.5879/share + CVR; adds at least $9.5M non-dilutive capital.
- Expanded royalty portfolio: economic interests in DSUVIA, XACIATO, Ovaprene (Ph3), and Sildenafil Cream.
- Launched first $50M stock buyback; cash $142.4M at March 31, 2024.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/791908/000119312524134777/0001193125-24-134777-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/791908/000119312524134777/d841331d8k.htm
  HTML page:      https://secwatch.observer/filing/0001193125-24-134777

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer